• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or keep ADHD medication during breastfeeding and pregnancy is challenging for women with the condition. There is a lack of information about how long-term exposure to these drugs can affect the foetus.

A study recently published in Molecular Psychiatry demonstrates that children exposed to adhd otc medication medication during pregnancy do not develop neurological disorders such as hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and taking ADHD medication need to evaluate the benefits of using it against the possible risks for the foetus. Doctors don't have the data needed to provide clear recommendations but they can provide information regarding benefits and risks that can aid pregnant women in making informed choices.

A study published in Molecular Psychiatry concluded that women who took ADHD medication in early pregnancy did not have a greater risk of fetal malformations or structural birth defects. Researchers used a large population-based study of case control to examine the prevalence of structural defects that were major in infants born to mothers who were taking stimulants during pregnancy. Clinical geneticists, pediatric cardiologists and other experts looked over the cases to confirm that the classification was correct and to minimize any bias.

The study of the researchers had some limitations. Most important, they were unable to distinguish the effects of the medication from the effects of the underlying disorder. This limitation makes it difficult to determine whether the small associations observed in the exposed groups are due to medication use or comorbidities that cause confusion. The researchers also did not examine the long-term effects for the offspring.

The study found that babies whose mothers had taken ADHD medication during pregnancy had a slightly higher chance of being admitted to the neonatal care unit (NICU), compared to mothers who didn't take any medication during pregnancy, or had stopped taking their medication before or during pregnancy. This was due to central nervous system-related disorders, and the increased risk of admission was not found to be influenced by the stimulant medications were taken during pregnancy.

Women who used stimulant ADHD medication during pregnancy also had an elevated chance of having a caesarean birth or having a child with an low Apgar score (less than 7). These increases appear to be unrelated to the type of medication taken during pregnancy.

The research suggests that the small risk associated with the use of ADHD medications during the early stages of pregnancy may be offset by the greater benefit for both mother and child from continued treatment for the woman's condition. Physicians should discuss the issue with their patients and, if possible, assist them in developing strategies to improve their coping abilities that may minimize the negative impact of her condition on her daily life and relationships.

Medication Interactions

As more women than ever before are being diagnosed with ADHD and being treated with medication, the dilemma of whether to keep or end treatment during pregnancy is a question that more and more physicians confront. Often, these decisions are made in the absence of solid and reliable evidence either way, so physicians must weigh what they know from their own experiences, those of other doctors, and what research suggests on the subject, along with their best judgment for each individual patient.

Particularly, the subject of possible risks to the infant can be difficult. Many of the studies on this issue are based on observations rather than controlled research and their conclusions are often contradictory. Additionally, the majority of studies limit their analysis to live births, which could undervalue the serious teratogenic effects that can cause abortion or termination of the pregnancy. The study presented in this journal club addresses these issues by analyzing data on live and deceased births.

The conclusion: While some studies have shown a positive association between ADHD medications prescribed for adhd and the risk of certain birth defects, other studies have found no connection, and most studies demonstrate a neutral or slightly negative impact. In all cases it is imperative to conduct a thorough analysis of the risks and benefits should be conducted.

It can be difficult, if not impossible for women with ADHD to stop taking their medication. In a recent article in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can lead to increased depression, feelings of isolation and family conflict for patients with ADHD. In addition, a decrease in medication can affect the ability to complete jobs and drive safely which are essential aspects of a normal life for many people with ADHD.

She suggests that women who are not sure whether to take the medication or discontinue it due to pregnancy, educate their family members, coworkers, and their friends about the condition, the impact on daily functioning and the advantages of staying on the current treatment. It can also help a woman feel confident about her decision. It is also worth noting that some medications can pass through the placenta so if the patient decides to stop taking her ADHD medication during pregnancy and breastfeeding, she must be aware of the possibility that traces of the drug could be transferred to the child.

Birth Defects Risk

As the use of ADHD drugs to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases as do concerns over the impact that these drugs could have on foetuses. A recent study published in the journal Molecular Psychiatry adds to the existing information on this topic. Researchers utilized two massive datasets to analyze over 4.3 million pregnant women and determine if stimulant medication use increased birth defects. While the overall risk remains low, the scientists discovered that the first-trimester exposure to ADHD medications prescribed for adhd was associated with a slightly higher rate of certain heart defects such as ventriculoseptal defect (VSD).

The authors of the study did not find any association between early medication usage and other congenital anomalies, like facial deformities or club feet. The results are in line with previous studies that have shown an increase, but not significant, in the risk of heart malformations in women who started taking ADHD medications prior to the time of the time of pregnancy. The risk was higher in the latter half of pregnancy, when a lot of women decide to stop taking their ADHD medications.

Women who took ADHD medication during the first trimester were more likely to require a caesarean delivery or have a low Apgar after delivery and have a baby who needed breathing assistance after birth. However, the authors of the study were not able to eliminate bias due to selection by limiting the study to women who didn't have any other medical conditions that could have contributed to the findings.

The researchers hope their study will aid in the clinical decisions of doctors who see pregnant women. They recommend that, while discussing the benefits and risks is important but the decision to stop or maintain medication must be based on each woman's requirements and the severity of her ADHD symptoms.

The authors also warn that while discontinuing the medications is an option, it isn't a recommended practice because of the high prevalence of depression and other mental health problems in women who are pregnant or recently postpartum. Research has also shown that women who stop taking their medication will have a tough transitioning to life without them once the baby is born.

Nursing

The responsibilities of a new mom can be overwhelming. Women who suffer from ADHD who must work through their symptoms while attending doctor appointments and preparing for the arrival of a child and getting used to new routines at home are often faced with a number of difficulties. Many women choose to continue taking their ADHD medication during pregnancy.

The risk for nursing infant is low because the majority of stimulant medications passes through breast milk at a low level. The amount of exposure to medications can vary depending upon the dosage, frequency of administration and the time of day. In addition, various medications enter the baby’s system via the gastrointestinal tract or breast milk. The impact on the health of a newborn isn't completely understood.

Because of the lack of evidence, some doctors may recommend stopping stimulant medication during the course of pregnancy. This is a difficult decision for the woman who must weigh the advantages of taking her medication as well as the risk to the fetus. As long as there is no more information, GPs should ask all pregnant patients about their history of ADHD and whether they are taking or planning to take medication during the perinatal time.

Numerous studies have demonstrated that women can continue to take their ADHD medication in a safe manner during pregnancy and while breast-feeding. As a result, many patients are choosing to do so, and in consultation with their doctor they have discovered that the benefits of maintaining their current medication outweigh any potential risks.

Women who suffer from ADHD who plan to breastfeed should seek advice from a specialist psychiatrist prior to becoming pregnant. They should discuss their medication with their doctor, and the pros and cons for continuing treatment. This includes non amphetamine adhd medication-pharmacological methods. Psychoeducation should also be provided to help women with Adhd Medication Over The Counter Uk be aware of their symptoms and the root cause, learn about available treatment options and strengthen existing coping strategies. This should involve an approach that is multidisciplinary, including the GP, obstetricians and psychiatry. Pregnancy counseling should include a discussion of a treatment plan for the mother and child, monitoring of signs of deterioration, and, if needed, adjustments to the medication regimen.